(L) Dr Shailesh Ayyangar and (R) Satish Mehta, with Antoine Ortoli (M)
Commenting on the partnership, Dr Shailesh Ayyangar, MD & VP, South Asia Sanofi India, and Sanofi-Synthelabo (India) said, "Sanofi is highly committed to the field of Oncology. Realizing that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology makes immense sense for both companies."
He further explained, "Doctors and patients will now have access ‘under one roof' to one of the most comprehensive and complementing oncology portfolios in India. Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business."
As per the agreement, while Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, Emcure will market and distribute these brands through its specialty unit.
Mr Satish Mehta, MD, Emcure Pharmaceuticals stated, "We are delighted to be identified as the partner-of-choice by Sanofi in India, and for being entrusted with such a prestigious global oncology portfolio. We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions. We are extremely optimistic about its prospects and committed to creating a long-term partnership with Sanofi."